Company profile for Omega Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

t Omega Therapeutics, we interrogate the central dogma to target the biological root of disease and change its course without altering nucleic acid sequences or the genetic code. We are focused on precision tuning to activate the human genome’s native capacity to treat and cure diseases — ultimately allowing for the advancement of medicine and a new future of disease management. This scientific insight drives our discov...
t Omega Therapeutics, we interrogate the central dogma to target the biological root of disease and change its course without altering nucleic acid sequences or the genetic code. We are focused on precision tuning to activate the human genome’s native capacity to treat and cure diseases — ultimately allowing for the advancement of medicine and a new future of disease management. This scientific insight drives our discovery and development of genomic modulators, called Omega Epigenomic Controllers™. We engineer them to precisely tune genomic activity to desired therapeutic levels through control of the GenomStats™.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
20 Acorn Park Drive Cambridge, MA 02140
Telephone
Telephone
617-949-4360
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.fiercebiotech.com/biotech/omega-halts-sole-clinical-stage-program-prioritize-novo-collab-and-liver-obesity-work

FIERCE BIOTECH
15 Nov 2024

https://www.globenewswire.com/news-release/2024/11/14/2981593/0/en/Omega-Therapeutics-Announces-Successful-Completion-of-Phase-1-Trial-for-Novel-Epigenomic-Controller-Prioritized-Pipeline-Leadership-Changes-and-Third-Quarter-2024-Financial-Results.html

GLOBENEWSWIRE
14 Nov 2024

https://www.globenewswire.com/news-release/2024/10/15/2963113/0/en/Omega-Therapeutics-to-Present-Multiple-Posters-Highlighting-Versatile-Platform-Capabilities-at-Upcoming-Scientific-Meetings.html

GLOBENEWSWIRE
15 Oct 2024

https://www.globenewswire.com/news-release/2024/09/17/2947286/0/en/Omega-Therapeutics-Announces-Publication-of-Epigenomic-Controller-OTX-2002-Preclinical-Data-in-Nature-Communications.html

GLOBENEWSWIRE
17 Sep 2024

https://www.globenewswire.com/news-release/2024/08/14/2929939/0/en/Omega-Therapeutics-Announces-Jennifer-Nelson-Ph-D-as-Senior-Vice-President-of-Research.html

GLOBENEWSWIRE
14 Aug 2024

https://www.globenewswire.com/news-release/2024/08/06/2924892/0/en/Omega-Therapeutics-Reports-Second-Quarter-2024-Financial-Results-and-Highlights-Recent-Company-Progress.html

GLOBENEWSWIRE
06 Aug 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty